Table 1.
Characteristics of the study population and adjusted odds ratios (ORs) for the intention of COVID‐19 vaccination in patients with psoriasis
| Psoriasis, n = 713 | Other skin conditions, n = 228 | OR (95% CI)a | |
| Age (years), mean (SD) | 56·1 (18·3) | 52·6 (10·5) | 1·27 (1·18–1·39) |
| Female, n (%) | 342 (48·0) | 117 (51·3) | 1·19 (1·12–1·23) |
| Type of therapy, n (%) | |||
| Systemic treatment | 102 (14·3) | 201 (88·2) | 1·02 (1·01–1·03) |
| Biologics | 611 (85·7) | 27 (11·8) | 1·48 (1·32–1·64) |
| Age of psoriasis onset (years), mean (SD) | 32 (11·0) | – | 0·98 (0·80–1·18) |
| History of smoking, n (%) | 484 (67·9) | 166 (72·8) | 1·03 (0·97–1·25) |
| Education level, n (%) | |||
| Low | 101 (14·2) | 38 (16·7) | 0·96 (0·78–1·15) |
| Medium | 163 (22·9) | 73 (32·0) | 0·99 (0·81–1·12) |
| High | 449 (63·0) | 117 (51·3) | 1·13 (1·08–1·27) |
| Comorbidities, n (%) | |||
| Psoriatic arthritis | 167 (23·4) | – | 1·18 (1·13–1·23) |
| COPD | 64 (9·0) | 18 (7·9) | 1·61 (1·49–1·73) |
| Heart conditions | 124 (17·4) | 32 (14) | 0·89 (0·74–1·08) |
| Chronic kidney disease | 49 (6·9) | 14 (6·1) | 1·04 (0·88–1·26) |
| Diabetes | 129 (18·1) | 46 (20·2) | 1·19 (1·12–1·26) |
| Obesity | 36 (5·5) | 16 (7·0) | 0·92 (0·83–1·02) |
| Solid organ transplant | 2 (0·3) | 1 (0·4) | 1·02 (0·98–1·04) |
| Malignancy | 86 (12·1) | 25 (11) | 1·15 (1·09–1·23) |
CI, confidence interval; COPD, chronic obstructive pulmonary disease. aPatients with psoriasis only.